5465-66-7

Usage

Uses

Used in Research and Development:
1-(4-bromo-2-nitrophenyl)piperidine is used as a research compound for the development of new pharmaceuticals. Its unique structure, which includes a bromine atom and a nitro group, makes it a valuable building block for the synthesis of biologically active compounds.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 1-(4-bromo-2-nitrophenyl)piperidine is used as an intermediate in the synthesis of various organic compounds. Its presence as a key structural component can contribute to the development of new drugs with specific therapeutic properties.
Used as a Ligand in Metal Ion Complexes:
1-(4-bromo-2-nitrophenyl)piperidine also serves as a ligand for the formation of metal ion complexes. This application is significant in various chemical processes and can lead to the creation of novel materials with specialized properties.
Overall, 1-(4-bromo-2-nitrophenyl)piperidine is a versatile compound with a wide range of applications in both the chemical and pharmaceutical sectors, making it an important asset for researchers and developers in these fields.

InChI:InChI=1/C11H13BrN2O2/c12-9-4-5-10(11(8-9)14(15)16)13-6-2-1-3-7-13/h4-5,8H,1-3,6-7H2

Upstream product

• 110-89-4 piperidine 
• 33696-00-3 4-bromo-1-methoxy-2-nitrobenzene 
• 16588-24-2 4-bromo-1-chloro-2-nitrobenzene 
• 364-73-8 4-Bromo-1-fluoro-2-nitrobenzene 
• 55321-64-7 (4-bromo-2-nitro-phenyl)-p-tolyl ether 
• 7697-37-2 nitric acid 
• 64-19-7 acetic acid 
• 3460-18-2 1,4-dibromo-2-nitrobenzene 

Downstream Products

• 1016877-65-8 5-bromo-2-(piperidin-1-yl)aniline 
• 885704-46-1 4-(3-nitro-4-(piperidin-1-yl)phenyl)morpholine 

Relevant academic research and scientific papers

Optimisation of 2-(N-phenyl carboxamide) triazolopyrimidine antimalarials with moderate to slow acting erythrocytic stage activity

Malaria is a devastating parasitic disease caused by parasites from the genus Plasmodium. Therapeutic resistance has been reported against all clinically available antimalarials, threatening our ability to control the disease and therefore there is an ongoing need for the development of novel antimalarials. Towards this goal, we identified the 2-(N-phenyl carboxamide) triazolopyrimidine class from a high throughput screen of the Janssen Jumpstarter library against the asexual stages of the P. falciparum parasite. Here we describe the structure activity relationship of the identified class and the optimisation of asexual stage activity while maintaining selectivity against the human HepG2 cell line. The most potent analogues from this study were shown to exhibit equipotent activity against P. falciparum multidrug resistant strains and P. knowlesi asexual parasites. Asexual stage phenotyping studies determined the triazolopyrimidine class arrests parasites at the trophozoite stage, but it is likely these parasites are still metabolically active until the second asexual cycle, and thus have a moderate to slow onset of action. Non-NADPH dependent degradation of the central carboxamide and low aqueous solubility was observed in in vitro ADME profiling. A significant challenge remains to correct these liabilities for further advancement of the 2-(N-phenyl carboxamide) triazolopyrimidine scaffold as a potential moderate to slow acting partner in a curative or prophylactic antimalarial treatment.

Synthesis, X-ray Structure Determination, and Comprehensive Photochemical Characterization of (Trifluoromethyl)diazirine-Containing TRPML1 Ligands

Potential (trifluoromethyl)diazirine-based TRPML1 ion channel ligands were designed and synthesized, and their structures were determined by single-crystal X-ray diffraction analysis. Photoactivation studies via 19F NMR spectroscopy and HPLC-MS analysis revealed distinct kinetical characteristics in selected solvents and favorable photochemical properties in an aqueous buffer. These photoactivatable TRPML activators represent useful and valuable tools for TRPML photoaffinity labeling combined with mass spectrometry.

KINASE INHIBITORS AND METHODS FOR MAKING AND USING

Disclosed embodiments concern kinase inhibitors, such as interleukin receptor associated kinases (IRAK) inhibitors, and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent a kinase-associated disease or condition, particularly an IRAK-associated disease or condition.

Synthesis and bioevaluation of 1-phenyl-pyrazole-4-carboxylic acid derivatives as potent xanthine oxidoreductase inhibitors

A diverse library of 1-phenyl-pyrazole-4-carboxylic acid derivatives were synthesized and evaluated for their inhibitory potency against xanthine oxidoreductase (XOR) in vitro and vivo, and the structure-activity relationship (SAR) analyses were also pres

Nitrogen-substituted phenyl pyrazole xanthine oxidoreductase inhibitor and preparation and application thereof

The invention belongs to the technical field of pharmaceutical and chemical industry and discloses nitrogen-substituted phenyl pyrazole xanthine oxidoreductase inhibitor and preparation and application thereof. The nitrogen-substituted phenyl pyrazole xan

Theoretical Calculations of Chemical Interactions. Part 4. Aromatic Nucleophilic Substitutions and SN2 Reactions of 4- and 6-Substituted 2-Nitroanisoles

The reactions of 4-R- and 6-R-2-nitroanisoles (R=Me, Br) in neat cyclohexylamine and piperidine have been studied.The reactions with cyclohexylamine lead to the respective aromatic nucleophilic substitution products while the reactions with piperidine mainly yield the substituted nitrophenols.It was found that 6-R-2-nitroanisoles react faster than the respective 4-R-2-nitroanisoles.The absence of the expected primary steric effect is thought to be due to the spatial arrangement of the methoxide group, which adopts a conformation perpendicular to the ring plane when it is surrounded by two ortho-substituents.CNDO and INDO calculations for different conformations of the substrates give support to this assumption.